✦ LIBER ✦

Incidence and severity of acute allograft rejection in liver transplant recipients treated with alfa interferon

✍ Scribed by Jain, Ashokkumar ;Demetris, Anthony J. ;Manez, Rafael ;Tsamanadas, Athanassisos C. ;Van Thiel, David ;Rakela, Jorge ;Starzl, Thomas E. ;Fung, John J.

Publisher: Wiley (John Wiley & Sons)
Year: 1998
Tongue: English
Weight: 195 KB
Volume: 4
Category: Article
ISSN: 1074-3022
DOI: 10.1002/lt.500040315

No coin nor oath required. For personal study only.

✦ Synopsis

Interferon alfa-2b (IFN-alpha) therapy has been shown to be effective in the treatment of viral hepatitis B (HBV) or viral hepatitis C (HCV) in patients who did not undergo transplantation. However, in allograft recipients, treatment with IFN-alpha often leads to allograft rejection. The aim of the present study was to determine if IFN-alpha therapy increases the incidence or severity of acute rejection in human liver allograft recipients. One hundred five orthotopic liver transplant (OLT) recipients with HBV (n = 32), HCV (n = 58), or Non A Non B Non C (n = 15) viral infections were treated with a 6-month course of IFN-alpha, 5 million U subcutaneously three times a week, which began 2 to 97 months after transplantation. The mean hepatitis activity index (HAI) at the beginning of the therapy was 10.1 +/- 3.0. The baseline immunosuppression was achieved by tacrolimus in 77 patients and by cyclosporine A (CyA) in 28 patients. Contemporaneous controls consisted of 132 OLT patients (100 who received tacrolimus and 32 who received CyA) who did not receive IFN-alpha. A retrospective analysis was performed on this group of patients. The incidence of rejection and the baseline immunosuppression were compared. All biopsies were reviewed without knowledge of clinical data and scored for HAI and for rejection activity index (RAI). The biochemical response to IFN-alpha was also examined. The mean baseline maintenance dose of prednisone was greater by 2 mg daily in patients who received IFN-alpha with tacrolimus compared with control patients who did not receive IFN-alpha with tacrolimus (IFN-alpha 5. 3 +/- 5.2 mg daily v controls 3.3 +/- 4.9 mg daily; P

📜 SIMILAR VOLUMES

Outcomes of acute rejection after interf

Outcomes of acute rejection after interferon therapy in liver transplant recipients

✍ Sammy Saab; Denise Kalmaz; Nupoor A. Gajjar; Jonathan Hiatt; Francisco Durazo; S 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 229 KB 👁 1 views

Interferon alfa has been increasingly used against recurrent hepatitis C (HCV) disease in post-liver transplant (LT) recipients. A serious potential adverse effect is acute rejection. We reviewed our experience using interferonbased therapy (interferon or pegylated interferon with or without ribavir

Long-term outcome of mycophenolate mofet

Long-term outcome of mycophenolate mofetil rescue therapy for resistant acute allograft rejection in pediatric liver transplant recipients

✍ Marion Margaret Aw; Anita Verma; Mohamed Rela; Nigel Heaton; Giorgina Mieli-Verg 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 88 KB 👁 1 views

Mycophenolate mofetil (MMF) has been used to rescue liver allografts with steroid-resistant rejection (SRR). However, the long-term outcome of these patients is not known. This study evaluates the long-term outcome of MMF rescue therapy for SRR in pediatric liver allograft recipients. Twenty-six chi

Anemia is not predictive of sustained vi

Anemia is not predictive of sustained virological response in liver transplant recipients with hepatitis C virus who are treated with pegylated interferon and ribavirin

✍ Michela Giusto; Maria Rodriguez; Laia Navarro; Angel Rubin; Victoria Aguilera; F 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 148 KB 👁 1 views

In the immunocompetent setting, antiviral therapy-related anemia has recently been shown to be associated with a sustained virological response (SVR). Our goal was to assess whether this is also true for liver transplantation (LT). We included 160 LT patients with recurrent hepatitis C virus (HCV) w

Prediction of sustained virological resp

Prediction of sustained virological response in liver transplant recipients with recurrent hepatitis C virus following combination pegylated interferon alfa-2b and ribavirin therapy using tissue hepatitis C virus reverse transcriptase polymerase chain reaction testing

✍ Guy W. Neff; Christopher B. O'Brien; Robert Cirocco; Marzia Montalbano; Maria de 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 69 KB 👁 2 views

The optimal duration of therapy for pegylated interferon combined with ribavirin in recurrent Hepatitis C virus (HCV) following liver transplantation is not known. We wanted to determine if testing for HCV in liver tissue by reverse transcriptase polymerase chain reaction (RT-PCR) was superior in pr